Giuseppe Maiolino, Miguel Angel Martinez Garcia, Davide Soranna, Antonella Zambon, Roberto Vettor, Gianfranco Parati, David Gozal, Martino F Pengo
{"title":"Calling for Action: The Need of Large-Scale Cohorts to Uncover the Cardiovascular Risk in Non-Sleepy Obstructive Sleep Apnea.","authors":"Giuseppe Maiolino, Miguel Angel Martinez Garcia, Davide Soranna, Antonella Zambon, Roberto Vettor, Gianfranco Parati, David Gozal, Martino F Pengo","doi":"10.1007/s40292-024-00680-y","DOIUrl":null,"url":null,"abstract":"<p><p>Since randomized clinical trials currently do not support continuous positive airway pressure treatment of asymptomatic obstructive sleep apnea (OSA) we proposed the Obesity, Symptoms, and CARdiovascular assessment (OSCAR) algorithm to aid clinicians in the management of asymptomatic low-risk moderate-severe OSA, focusing on weight loss, symptoms and cardiovascular disease (CVD) risk assessment. Exploiting the data of the Sleep Heart Health Study we selected subjects with a body mass index (BMI) < 30 Kg/m<sup>2</sup>, no history of CVD or sleepiness and compared 552 patients with moderate-severe OSA (OSCAR(-)) to 916 individuals without OSA (No-OSA). After adjusting for age, gender, and BMI, there was no significant difference in the risk of major adverse cardiovascular events (MACE) between OSCAR(-) and No-OSA (1.05; 95%CI 0.81-1.37). The study suggests that low-risk moderate-severe OSA patients may not have a greater risk of MACE compared to those without OSA and highlights the need for further research on this topic.</p>","PeriodicalId":12890,"journal":{"name":"High Blood Pressure & Cardiovascular Prevention","volume":" ","pages":""},"PeriodicalIF":3.1000,"publicationDate":"2024-10-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"High Blood Pressure & Cardiovascular Prevention","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1007/s40292-024-00680-y","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PERIPHERAL VASCULAR DISEASE","Score":null,"Total":0}
引用次数: 0
Abstract
Since randomized clinical trials currently do not support continuous positive airway pressure treatment of asymptomatic obstructive sleep apnea (OSA) we proposed the Obesity, Symptoms, and CARdiovascular assessment (OSCAR) algorithm to aid clinicians in the management of asymptomatic low-risk moderate-severe OSA, focusing on weight loss, symptoms and cardiovascular disease (CVD) risk assessment. Exploiting the data of the Sleep Heart Health Study we selected subjects with a body mass index (BMI) < 30 Kg/m2, no history of CVD or sleepiness and compared 552 patients with moderate-severe OSA (OSCAR(-)) to 916 individuals without OSA (No-OSA). After adjusting for age, gender, and BMI, there was no significant difference in the risk of major adverse cardiovascular events (MACE) between OSCAR(-) and No-OSA (1.05; 95%CI 0.81-1.37). The study suggests that low-risk moderate-severe OSA patients may not have a greater risk of MACE compared to those without OSA and highlights the need for further research on this topic.
由于随机临床试验目前并不支持对无症状阻塞性睡眠呼吸暂停(OSA)进行持续气道正压治疗,因此我们提出了肥胖、症状和心血管评估(OSCAR)算法,以帮助临床医生管理无症状低风险中度重度 OSA,重点是减轻体重、症状和心血管疾病(CVD)风险评估。利用睡眠心脏健康研究的数据,我们选择了体重指数(BMI)为2、无心血管疾病或嗜睡病史的受试者,并将552名中重度OSA患者(OSCAR(-))与916名无OSA患者(No-OSA)进行了比较。在对年龄、性别和体重指数进行调整后,OSCAR(-)和No-OSA发生主要不良心血管事件(MACE)的风险没有明显差异(1.05;95%CI 0.81-1.37)。该研究表明,与无 OSA 患者相比,低风险的中度-重度 OSA 患者发生 MACE 的风险可能并不大,并强调了进一步研究该课题的必要性。
期刊介绍:
High Blood Pressure & Cardiovascular Prevention promotes knowledge, update and discussion in the field of hypertension and cardiovascular disease prevention, by providing a regular programme of independent review articles covering key aspects of the management of hypertension and cardiovascular diseases. The journal includes: Invited ''State of the Art'' reviews. Expert commentaries on guidelines, major trials, technical advances.Presentation of new intervention trials design.''Pros and Cons'' or round tables on controversial issues.Statements on guidelines from hypertension and cardiovascular scientific societies.Socio-economic issues.Cost/benefit in prevention of cardiovascular diseases.Monitoring of healthcare systems.News and views from the Italian Society of Hypertension (including abstracts).All manuscripts are subject to peer review by international experts. Letters to the editor are welcomed and will be considered for publication.